Publication - Yassine Lab

Publications

Yassine HN

Increased cerebrospinal fluid and plasma apoE glycosylation is associated with reduced levels of Alzheimer's disease biomarkers January 7, 2025
The apolipoprotein E ( APOE ) ε4 allele is the strongest genetic risk factor for Alzheimer's disease (AD). ApoE is glycosylated with an O-linked Core-1 sialylated glycan at several sites, yet the impact and function of this glycosylation on AD biomarkers remains unclear. We examined apoE glycosylation in a cohort of cerebrospinal fluid (CSF, n=181) […]
Dobrin Nedelkov
Development of Calcium-Dependent Phospholipase A2 Inhibitors to Target Cellular Senescence and Oxidative Stress in Neurodegenerative Diseases November 22, 2024
Significance: Cellular senescence is a critical process underlying aging and is associated with age-related diseases such as Alzheimer's disease. Lipids are implicated in cellular senescence. Fatty acids, particularly eicosanoids, have been associated with various forms of senescence and inflammation, and the associated reactive oxygen species production has been proposed as a therapeutic target for mitigating […]
Cristelle Hugo
APOE ε4 and Dietary Patterns in Relation to Cognitive Function: An Umbrella Review of Systematic Reviews November 5, 2024
CONCLUSION: This review identifies notable gaps in the literature, such as a shortage of studies conducted in middle-aged and cognitively healthy APOE ε4 carriers assessing the impact of dietary interventions and provides suggestions for novel trial designs.
Thomas J Urich
Designing Newer Omega-3 Supplementation Trials for Cognitive Outcomes: A Systematic Review Guided Analysis October 18, 2024
CONCLUSIONS: We recommend that newer n-3 PUFA supplement trials targeting AD prevention be personalized. For the general population, the null hypothesis appears to be correct, and future interventions are needed to identify and test dietary patterns that include PUFA-rich food rather than supplements.
Hussein N Yassine
Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference July 20, 2024
INTRODUCTION: The apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer's disease (AD), with distinct apoE isoforms exerting diverse effects. apoE influences not only amyloid-beta and tau pathologies but also lipid and energy metabolism, neuroinflammation, cerebral vascular health, and sex-dependent disease manifestations. Furthermore, ancestral background may significantly impact the link […]
Courtney M Kloske
Sex Specific Associations of Sex hormone With Brain Volumes and Cerebral Blood Flow: A Cross Sectional Observational Study Within the Look AHEAD Type 2 Diabetes Cohort May 15, 2024
CONCLUSIONS: In postmenopausal females with Type 2 Diabetes with overweight and obesity, detectable levels of total testosterone were associated greater brain volume relative to intracranial volume, suggesting a protective role for testosterone in female brain health. Our findings are limited by a small sample size and low sensitivity of hormone assays. Our suggestive findings can […]
Dhananjay Vaidya
Effects of APOE4 on omega-3 brain metabolism across the lifespan April 12, 2024
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs), such as docosahexaenoic acid (DHA), have important roles in human nutrition and brain health by promoting neuronal functions, maintaining inflammatory homeostasis, and providing structural integrity. As Alzheimer's disease (AD) pathology progresses, DHA metabolism in the brain becomes dysregulated, the timing and extent of which may be influenced by the […]
Brandon Ebright
Can the gut microbiome inform the effects of omega-3 fatty acid supplementation trials on cognition? January 3, 2024
PURPOSE OF REVIEW: Most omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation clinical trials report inconsistent or null findings on measures of cognition or Alzheimer's disease (AD) with a relatively large variability in the response to n-3 PUFA supplementation. The purpose of this review is to identify whether the gut microbiome together with the metabolome can […]
Bilal E Kerman
Synthesis and Preclinical Evaluation of 22-[<sup>18</sup>F]Fluorodocosahexaenoic Acid as a Positron Emission Tomography Probe for Monitoring Brain Docosahexaenoic Acid Uptake Kinetics December 4, 2023
Docosahexaenoic acid [22:6(n-3), DHA], a polyunsaturated fatty acid, has an important role in regulating neuronal functions and in normal brain development. Dysregulated brain DHA uptake and metabolism are found in individuals carrying the APOE4 allele, which increases the genetic risk for Alzheimer's disease (AD), and are implicated in the progression of several neurodegenerative disorders. However, […]
Marlon Vincent V Duro
Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia October 24, 2023
CONCLUSIONS: Findings from PreventE4 will clarify the brain delivery of DHA in individuals carrying the APOE ε4 allele with implications for dementia prevention strategies. Trial was registered as NCT03613844.
H N Yassine
State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer's Disease August 23, 2023
Type 2 diabetes mellitus (T2DM) is common and increasing in prevalence worldwide, with devastating public health consequences. While peripheral insulin resistance is a key feature of most forms of T2DM and has been investigated for over a century, research on brain insulin resistance (BIR) has more recently been developed, including in the context of T2DM […]
Elizabeth M Rhea
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele May 23, 2023
Carrying the apolipoprotein E (ApoE) Ɛ4 allele is associated with an increased risk of cerebral amyloidosis and late-onset Alzheimer's disease, but the degree to which apoE glycosylation affects its development is not clear. In a previous pilot study, we identified distinct total and secondary isoform-specific cerebral spinal fluid (CSF) apoE glycosylation profiles, with the E4 […]
Cristiana J Meuret
Associations of ApoE4 status and DHA supplementation on plasma and CSF lipid profiles and entorhinal cortex thickness March 23, 2023
Apolipoprotein ε allele 4 (APOE4) influences the metabolism of polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA). The entorhinal cortex (EC) in the brain is affected early in Alzheimer's disease and is rich in DHA. The purpose of this study is to identify the effect of APOE4 and DHA lipid species on the EC. […]
Mikaila Ann Bantugan
Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias December 8, 2022
Disturbances in the brain's capacity to meet its energy demand increase the risk of synaptic loss, neurodegeneration, and cognitive decline. Nutritional and metabolic interventions that target metabolic pathways combined with diagnostics to identify deficits in cerebral bioenergetics may therefore offer novel therapeutic potential for Alzheimer's disease (AD) prevention and management. Many diet-derived natural bioactive components […]
Hussein N Yassine
APOE ε4 and Alzheimer's disease diagnosis associated differences in L-carnitine, GBB, TMAO, and acylcarnitines in blood and brain November 27, 2022
BACKGROUND: The apolipoprotein E (APOE) ε4 allele, involved in fatty acid (FA) metabolism, is a major genetic risk factor for Alzheimer's disease (AD). This study examined the influence of APOE genotypes on blood and brain markers of the L-carnitine system, necessary for fatty acid oxidation (FAO), and their collective influence on the clinical and pathological […]
Claire J C Huguenard

Arellanes IC; Choe N; Solomon V; He X; Kavin B; Martinez AE; Kono N; Buennagel DP; Hazra N; Kim G; D'Orazio LM; McCleary C; Sagare A; Zlokovic BV; Hodis HN; Mack WJ; Chui HC; Harrington MG; Braskie MN; Schneider LS; Yassine HN, 2020. Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. EBioMedicine 59:102883

Tomaszewski N; He X; Solomon V; Lee M; Mack WJ; Quinn JF; Braskie MN; Yassine HN, 2020. Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimer's Disease Cooperative Study-Sponsored DHA Clinical Trial. J Alzheimers Dis 74(3):975-990

Espeland MA; Hayden KM; Lockhart SN; Yassine HN; Hoscheidt S; Yasar S; Luchsinger JA; Neiberg RH; Diaz Brinton R; Carmichael O, 2020. Sex-Related Differences in Brain Volumes and Cerebral Blood Flow Among Overweight and Obese Adults With Type 2 Diabetes: Exploratory Analyses From the Action for Health in Diabetes Brain Magnetic Resonance Imaging Study. J Gerontol A Biol Sci Med Sci 75(4):771-778

Yassine HN; Finch CE, 2020. APOE Alleles and Diet in Brain Aging and Alzheimer's Disease. Front Aging Neurosci 12:150

Yassine HN; Anderson A; Brinton R; Carmichael O; Espeland MA; Hoscheidt S; Hugenschmidt CE; Keller JN; Peters A; Pi-Sunyer X, 2020. Do menopausal status and APOE4 genotype alter the long-term effects of intensive lifestyle intervention on cognitive function in women with type 2 diabetes mellitus? Neurobiol Aging 92:61-72

Hu Y; Meuret C; Go S; Yassine HN; Nedelkov D, 2020. Simple and Fast Assay for Apolipoprotein E Phenotyping and Glycotyping: Discovering Isoform-Specific Glycosylation in Plasma and Cerebrospinal Fluid. J Alzheimers Dis 76(3):883-893

Rawat V; Wang S; Sima J; Bar R; Liraz O; Gundimeda U; Parekh T; Chan J; Johansson JO; Tang C; Chui HC; Harrington MG; Michaelson DM; Yassine HN, 2019. ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes. J Neurosci 39(48):9611-9622

Kegulian NC; Ramms B; Horton S; Trenchevska O; Nedelkov D; Graham MJ; Lee RG; Esko JD; Yassine HN; Gordts PLSM, 2019. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. Arterioscler Thromb Vasc Biol 39(10):2145-2156

Lee S; Parekh T; King SM; Reed B; Chui HC; Krauss RM; Yassine HN, 2019. Low-Density Lipoprotein Particle Size Subfractions and Cerebral Amyloidosis. J Alzheimers Dis 68(3):983-990

Yassine HN, 2017. Targeting prodromal Alzheimer's disease: too late for prevention? Lancet Neurol 16(12):946-947

Yassine HN; Schneider LS, 2017. Lessons from the Multidomain Alzheimer Preventive Trial. Lancet Neurol 16(8):585-586

Jeffs JW; Ferdosi S; Yassine HN; Borges CR, 2017. Ex vivo instability of glycated albumin: A role for autoxidative glycation. Arch Biochem Biophys 629:36-42

Mendoza S; Trenchevska O; King SM; Nelson RW; Nedelkov D; Krauss RM; Yassine HN, 2017. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions. J Clin Lipidol 11(1):224-233.e2

Yassine HN; Croteau E; Rawat V; Hibbeln JR; Rapoport SI; Cunnane SC; Umhau JC, 2017. DHA brain uptake and APOE4 status: a PET study with [1-¹¹C]-DHA. Alzheimers Res Ther 9(1):23

Yassine HN; Braskie MN; Mack WJ; Castor KJ; Fonteh AN; Schneider LS; Harrington MG; Chui HC, 2017. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. JAMA Neurol 74(3):339-347

Yassine HN; Trenchevska O; Dong Z; Bashawri Y; Koska J; Reaven PD; Nelson RW; Nedelkov D, 2016. The association of plasma cystatin C proteoforms with diabetic chronic kidney disease. Proteome Sci 14:7

Yassine HN; Feng Q; Chiang J; Petrosspour LM; Fonteh AN; Chui HC; Harrington MG, 2016. ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease. J Am Heart Assoc 5.

Yassine HN; Feng Q; Azizkhanian I; Rawat V; Castor K; Fonteh AN; Harrington MG; Zheng L; Reed BR; DeCarli C; Jagust WJ; Chui HC, 2016. Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis. JAMA Neurol 73(10):1208-1216

Trenchevska O; Yassine HN; Borges CR; Nelson RW; Nedelkov D, 2016. Development of quantitative mass spectrometric immunoassay for serum amyloid A. Biomarkers 21(8):743-751

Yassine HN; Rawat V; Mack WJ; Quinn JF; Yurko-Mauro K; Bailey-Hall E; Aisen PS; Chui HC; Schneider LS, 2016. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther 8:25

Azizkhanian I; Trenchevska O; Bashawri Y; Hu J; Koska J; Reaven PD; Nelson RW; Nedelkov D; Yassine HN, 2016. Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. J Clin Lipidol 10(4):808-815

Yassine HN; Trenchevska O; Ramrakhiani A; Parekh A; Koska J; Walker RW; Billheimer D; Reaven PD; Yen FT; Nelson RW; Goran MI; Nedelkov D, 2015. The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides. PLoS One 10(12):e0144138

Kimzey MJ; Kinsky OR; Yassine HN; Tsaprailis G; Stump CS; Monks TJ; Lau SS, 2015. Site specific modification of the human plasma proteome by methylglyoxal. Toxicol Appl Pharmacol 289(2):155-62

Yassine HN; Trenchevska O; He H; Borges CR; Nedelkov D; Mack W; Kono N; Koska J; Reaven PD; Nelson RW, 2015. Serum amyloid a truncations in type 2 diabetes mellitus. PLoS One 10(1):e0115320

Yassine HN; Jackson AM; Reaven PD; Nedelkov D; Nelson RW; Lau SS; Borchers CH, 2014. The Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease. Transl Proteom 4-5:18-24

Yassine HN; Belopolskaya A; Schall C; Stump CS; Lau SS; Reaven PD, 2014. Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. Metabolism 63(5):727-34

Yassine HN; Jackson AM; Borges CR; Billheimer D; Koh H; Smith D; Reaven P; Lau SS; Borchers CH, 2014. The application of multiple reaction monitoring and multi-analyte profiling to HDL proteins. Lipids Health Dis 13:8

Taylor A; Westveld AH; Szkudlinska M; Guruguri P; Annabi E; Patwardhan A; Price TJ; Yassine HN, 2013. The use of metformin is associated with decreased lumbar radiculopathy pain. J Pain Res 6:755-63

Melemedjian OK; Yassine HN; Shy A; Price TJ, 2013. Proteomic and functional annotation analysis of injured peripheral nerves reveals ApoE as a protein upregulated by injury that is modulated by metformin treatment. Mol Pain 9:14

Kimzey MJ; Yassine HN; Riepel BM; Tsaprailis G; Monks TJ; Lau SS, 2011. New site(s) of methylglyoxal-modified human serum albumin, identified by multiple reaction monitoring, alter warfarin binding and prostaglandin metabolism. Chem Biol Interact 192(1-2):122-8

Yassine HN; Davis-Gorman G; Stump CS; Thomson SS; Peterson J; McDonagh PF, 2010. Effect of glucose or fat challenge on aspirin resistance in diabetes. Int J Endocrinol 2010:820876

Yassine HN; Davis-Gorman G; Stump CS; Thomson SS; Peterson J; McDonagh PF, 2010. Clinical determinants of aspirin resistance in diabetes. Diabetes Res Clin Pract 90(1):e19-21

Yassine HN; Marchetti CM; Krishnan RK; Vrobel TR; Gonzalez F; Kirwan JP, 2009. Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults--a randomized clinical trial. J Gerontol A Biol Sci Med Sci 64(1):90-5

Publication list retrieved from NCBI using ImpactPubs

Publications

Yassine HN

Quick Links

Get In Touch